Ceruletide

Summary

Ceruletide is a synthetic decapeptide that mimics the gastrointestinal hormone cholecystokinin (CCK). It is approved for parenteral use as an adjunct in radiographic examinations of the gallbladder and small intestine and has been investigated for therapeutic roles such as stimulating gut motility after surgery, relieving certain pain states, and treating movement disorders.

Mechanism of Action

Ceruletide binds with high affinity to CCK receptors, especially the CCK2 subtype, triggering the classic cholecystokinetic cascade. Activation of these receptors in the gastrointestinal tract induces coordinated duodenal‑to‑ileal propulsion, gallbladder contraction, and pancreatic enzyme secretion. In the central nervous system, CCK2 signaling has been linked to modulation of inflammatory and persistent pain pathways, which may underlie the peptide’s reported analgesic effects.

What the Research Shows

Early clinical work described ceruletide as a potent cholecystokinetic agent useful for diagnostic imaging and for stimulating motility in postoperative ileus, intestinal atony, and chronic fecal stasis. A 2002 review listed it among many agents tested for postoperative ileus, noting limited efficacy and adverse‑effect concerns. Preclinical studies show nanogram‑level analgesia when administered centrally, and a 2020 article highlighted its potential as an intrathecal analgesic for cancer‑related pain. Randomised trials for tardive dyskinesia found no significant benefit, and a Cochrane review concluded the evidence is inconclusive. Animal studies also reported ceruletide‑induced grooming without feeding changes, suggesting distinct neurobehavioral actions.

Reported Benefits

The primary, well‑established benefit is its ability to provoke robust gallbladder contraction and pancreatic secretion, making it valuable for diagnostic radiography of the biliary and small‑bowel systems. In therapeutic contexts, modest evidence supports use in stimulating gut motility after abdominal surgery, and preclinical data suggest potent analgesic activity via CCK2 receptors, especially when delivered intrathecally. These effects are dose‑dependent and observed at microgram to nanogram levels in experimental settings.

Limitations of the Evidence

Clinical efficacy for postoperative ileus remains modest, with many studies reporting limited or inconsistent benefit. Analgesic claims are largely preclinical; human data are sparse and confined to early exploratory trials. Randomised trials for tardive dyskinesia showed no improvement over placebo, and systematic reviews label the evidence as inconclusive. Small sample sizes, heterogeneous dosing, and a lack of large‑scale trials limit confidence in any therapeutic claims beyond diagnostic use.

Safety Considerations

Ceruletide is generally well tolerated at diagnostic doses, but transient gastrointestinal side effects—nausea, vomiting, and abdominal discomfort—are common. Rare cardiovascular reactions such as hypotension and tachycardia have been reported. No serious long‑term toxicity has been documented, yet the potential for dose‑related adverse events warrants monitoring, especially when higher therapeutic doses are employed for motility or analgesia.

How It Is Administered

The peptide is supplied as a sterile parenteral solution and can be given intramuscularly, intravenously, or subcutaneously. Diagnostic protocols typically involve a single bolus injection to provoke gallbladder contraction before imaging. Therapeutic regimens, when investigated, have used similar routes but may require repeated dosing or continuous infusion, depending on the clinical context.

Routes of Administration

Goals & Uses

• Pancreatic secretion stimulationResearchHigh
• Treatment of paralytic ileusTherapeuticModerate
• Pancreatic exocrine function testingDiagnosticHigh
• CCK receptor pharmacologyResearchHigh
• Induction of experimental pancreatitisResearchHigh
• Diagnostic gallbladder stimulationDiagnosticModerate
• Appetite suppression researchResearchLow
• Potential constipation therapyTherapeuticLow
• Gallbladder function testingDiagnosticHigh

Contraindications

• Known hypersensitivity to ceruletideAllergyHigh
• Hypersensitivity to ceruletideImmunologicHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Severe intestinal obstructionGastrointestinalModerate
• Biliary obstructionBiliaryHigh
• Acute pancreatitisGastrointestinalHigh
• Pancreatic duct obstructionGastrointestinalHigh
• Acute cholecystitisGastrointestinalHigh

Adverse Effects

• Abdominal cramping/painGastrointestinalCommon
• Hypersensitivity/anaphylaxisImmunologicalRare
• HypotensionCardiovascularRareLow blood pressure
• FlushingVascularCommonWarmth and redness of the skin
• Nausea and vomitingGastrointestinalCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Acute pancreatitisGastrointestinalRare
• DiarrheaGastrointestinalUncommonLoose or frequent stools
• Abdominal painGastrointestinalCommonPain or discomfort in the abdomen

Drug Interactions

• CCK receptor antagonists (e.g., lorglumide)High
• Other secretagogues (e.g., secretin)Moderate
• AtropineModerate
• Anticholinergic agentsModerate
• Opioid analgesicsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Pediatric patientsAgeRelative
• Elderly patientsAgeRelative
• Pregnant womenReproductiveRelative
• PediatricsAgeRelative
• Patients with known gallstonesGastrointestinalRelative

Regulatory Status

• European UnionUnapprovedNot authorized for clinical use
• United StatesUnapprovedAvailable only for investigational or research use
• United KingdomUnapprovedClassed as a research chemical

Not approved for therapeutic use in the United States or European Union; available only for investigational or research purposes.

Evidence & Sources

• Postoperative ileus: progress towards effective management
  Journal ArticleModerateHolte K, Kehlet H2002-01-01T00:00:00.000000Z
• Rediscovery of Ceruletide, a CCK Agonist, as an Analgesic Drug
  Journal ArticleModerateKeppel Hesselink JM2020-01-01T00:00:00.000000Z
• Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent
  Journal ArticleModerateVincent ME, Wetzner SM, Robbins AH1982-01-01T00:00:00.000000Z
• Bombesin and ceruletide-induced grooming and inhibition of ingestion in the rat
  Journal ArticleModerateKulkosky PJ1988-01-01T00:00:00.000000Z
• The treatment of tardive dyskinesia--a systematic review and meta-analysis
  Journal ArticleHighSoares KV, McGrath JJ1999-01-01T00:00:00.000000Z
• Miscellaneous treatments for neuroleptic-induced tardive dyskinesia
  Journal ArticleHighSoares-Weiser KV, Joy C2003-01-01T00:00:00.000000Z

Frequently Asked Questions